Nammi Therapeutics Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $30M

  • Investors
  • 3

Nammi Therapeutics General Information

Description

Operator of an immunotherapy company intended to provide improved treatment of cancer. The company combines immune-modulating prodrugs into lipid nanoparticles for selective delivery to tumors as well as to fight cancer without the serious side effects associated with chemotherapy, enabling patients to receive efficient treatment and recover at a faster speed

Contact Information

Website
www.nammirx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 10940 Wilshire Boulevard
  • Suite 600
  • Los Angeles, CA 90024
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 10940 Wilshire Boulevard
  • Suite 600
  • Los Angeles, CA 90024
  • United States

Nammi Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nammi Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series B) 01-Jul-2024 $30M Completed Pre-Clinical Trials
5. Later Stage VC (Series B1) 03-Mar-2023 Completed Pre-Clinical Trials
4. Grant 15-Dec-2022 Completed Pre-Clinical Trials
3. Early Stage VC (Series B) 01-Jan-2020 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 01-Jan-2019 $10M $10M Completed Pre-Clinical Trials
1. Accelerator/Incubator Completed Pre-Clinical Trials
To view Nammi Therapeutics’s complete valuation and funding history, request access »

Nammi Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B-1
Series B
Series A 12,500,000 $0.000100 $0.8 $0.8 1x $0.8 34.97%
To view Nammi Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Nammi Therapeutics Patents

Nammi Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026117686-A1 Fusion protein composition(s) comprising masked type i interferons (ifnα and ifnβ) for use in the treatment of cancer and methods thereof Pending 27-Nov-2024
US-12788819-B2 Formulated and/or co-formulated liposome compositions containg tgfβ antagonist prodrugs useful in the treatment of cancer and methods thereof Active 10-Jul-2023
AU-2023232077-A1 Formulated and/or co-formulated lipid nanocarriers compositions containing toll-like receptor ("tlr") agonist prodrugs useful in the treatment of cancer and methods thereof Pending 10-Mar-2022
EP-4489784-A1 Formulated and/or co-formulated lipid nanocarriers compositions containing toll-like receptor ("tlr") agonist prodrugs useful in the treatment of cancer and methods thereof Pending 10-Mar-2022
US-20240108732-A1 Formulated and/or co-formulated lipid nanocarriers compositions containing toll-like receptor ("tlr") agonist prodrugs useful in the treatment of cancer and methods thereof Pending 10-Mar-2022 A61K31/522
To view Nammi Therapeutics’s complete patent history, request access »

Nammi Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nammi Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Myeloma Investment Fund Not-For-Profit Venture Capital Minority
California Institute for Regenerative Medicine Government
Magnify Accelerator/Incubator
To view Nammi Therapeutics’s complete investors history, request access »

Nammi Therapeutics Acquisitions (1)

Nammi Therapeutics’s most recent deal was a Merger/Acquisition with Qwixel Therapeutics. The deal was made on 01-Jan-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Qwixel Therapeutics 01-Jan-2021 Merger/Acquisition Drug Discovery
To view Nammi Therapeutics’s complete acquisitions history, request access »

Nammi Therapeutics FAQs

  • When was Nammi Therapeutics founded?

    Nammi Therapeutics was founded in 2018.

  • Where is Nammi Therapeutics headquartered?

    Nammi Therapeutics is headquartered in Los Angeles, CA.

  • What is the size of Nammi Therapeutics?

    Nammi Therapeutics has 8 total employees.

  • What industry is Nammi Therapeutics in?

    Nammi Therapeutics’s primary industry is Drug Discovery.

  • Is Nammi Therapeutics a private or public company?

    Nammi Therapeutics is a Private company.

  • What is the current valuation of Nammi Therapeutics?

    The current valuation of Nammi Therapeutics is .

  • What is Nammi Therapeutics’s current revenue?

    The current revenue for Nammi Therapeutics is .

  • How much funding has Nammi Therapeutics raised over time?

    Nammi Therapeutics has raised $66.5M.

  • Who are Nammi Therapeutics’s investors?

    Myeloma Investment Fund, California Institute for Regenerative Medicine, and Magnify have invested in Nammi Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process